Table 3 Factors associated with progression criteria usage, feasibility as the primary outcome, and feasibility outcome for sample size justification
Variable | Use of progression criteria | Primary feasibility outcome | Sample size based on feasibility | |||
|---|---|---|---|---|---|---|
OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
Publication year | 1.26 (0.90–1.74) | 0.174 | 1.39 (1.06–1.83) | 0.017 | 1.51 (1.06–2.15) | 0.023 |
Impact factor | 1.01 (0.96–1.06) | 0.717 | 0.98 (0.92–1.04) | 0.433 | 0.93 (0.81–1.07) | 0.324 |
Funding | ||||||
Industry | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |||
Public or private | 1.69 (0.51–5.63) | 0.395 | 1.34 (0.51–3.47) | 0.552 | 1.17 (0.34–4.04) | 0.803 |
No reported funding | 0.31 (0.06–1.59) | 0.162 | 0.33 (0.1–1.07) | 0.066 | 0.47 (0.11–2.03) | 0.313 |
Intervention type | ||||||
Non-pharmacological | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |||
Pharmacological | 0.51 (0.2–1.3) | 0.159 | 0.41 (0.19–0.9) | 0.025 | 0.95 (0.38–2.36) | 0.908 |
WHO region | ||||||
Americas | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |||
E. Mediterranean | 0.99 (0.11–9.3) | 0.996 | 0.42 (0.05–3.74) | 0.440 | 0.94 (0.10–8.54) | 0.955 |
Europe | 1.30 (0.46–3.67) | 0.614 | 1.28 (0.56–2.96) | 0.557 | 1.21 (0.40–3.67) | 0.733 |
South-East Asia | 0.80 (0.09–7.48) | 0.846 | 0.32 (0.04–2.81) | 0.301 | 0.53 (0.06–4.85) | 0.577 |
Western Pacific | 0.99 (0.3–3.24) | 0.983 | 0.74 (0.28–1.94) | 0.540 | 1.00 (0.30–3.26) | 0.995 |
AIC | 169.8 | 223.5 | 155.7 | |||